ASH2018 注目テーマ Plenary Session #6

未治療高齢者CLLに対するイブルチニブ投与は
従来のリツキシマブ併用化学療法よりPFSを延長 Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202

Jennifer A. Woyach（The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH）